Approval for a change in repetition rate from 200 hz to 400 hz.  The device, as modified, will be marketed under the trade name allegretto wave eye-q excimer laser system and is indicated for laser assisted in situ keratomileusis (lasik) in patients who are 18 years of age or older:  1) for the reduction or elimination of myopia of up to -12.0 diopters (d) of sphere and up to -6.0 d of astigmatism at the spectacle plane in patients with documentation of a stable manifest refraction defined as <=0.50 d of preoperative spherical equivalent shift over one year prior to surgery; and 2) for the reduction or elimination of hyperopic refractive errors up to +6.0 d of sphere with and without astigmatic refractive errors up to 5.0 d at the spectacle plane, with a maximum manifest refraction spherical equivalent (mrse) of +6.0 d in patients with documentation of a stable manifest refraction defined as <=0.50 d of preoperative spherical equivalent shift over one year prior to surgery, exclusive of changes due to unmasking latent hyperopia.